Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1624KXH

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	3	MAR 16	CASREACT coverage extended
NEWS	4	MAR 20	MARPAT now updated daily
NEWS	5	MAR 22	LWPI reloaded
NEWS	6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	10	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS	11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	12	MAY 01	New CAS web site launched
NEWS	13	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS	14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	17	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS	18	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS	19	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS	20	JUN 29	STN Viewer now available
NEWS	21	JUN 29	STN Express, Version 8.2, now available
NEWS	22	JUL 02	LEMBASE coverage updated
NEWS	23	JUL 02	LMEDLINE coverage updated
NEWS	24	JUL 02	SCISEARCH enhanced with complete author names
NEWS	25	JUL 02	CHEMCATS accession numbers revised
NEWS	26	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS	27	JUL 16	CAplus enhanced with French and German abstracts
NEWS	28	JUL 18	CA/CAplus patent coverage enhanced
NEWS	29	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	30	JUL 30	USGENE now available on STN

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:17:06 ON 31 JUL 2007

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 13:17:12 ON 31 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JUL 2007 HIGHEST RN 943719-65-1
DICTIONARY FILE UPDATES: 30 JUL 2007 HIGHEST RN 943719-65-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10528601.str





```
chain nodes :
16  23  25
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  17  18  19  20  21  22
chain bonds :
6-9  7-16  16-17
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-11  8-9  9-10  10-11  10-12  11-15  12-13
13-14  14-15  17-18  17-22  18-19  19-20  20-21  21-22
exact/norm bonds :
7-8  7-11  7-16  8-9
exact bonds :
6-9  9-10  16-17
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  10-11  10-12  11-15  12-13  13-14  14-15  17-18
17-22  18-19  19-20  20-21  21-22
isolated ring systems :
containing 1 : 7 : 17 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:CLASS  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:CLASS  24:Atom  25:CLASS  26:Atom



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 13:17:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       40 TO ITERATE

100.0% PROCESSED       40 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          421 TO     1179
PROJECTED ANSWERS:               3 TO      163

L2             3 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 13:17:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      808 TO ITERATE

100.0% PROCESSED      808 ITERATIONS                               13 ANSWERS
SEARCH TIME: 00.00.01

L3            13 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             172.10     172.31

FILE 'CAPLUS' ENTERED AT 13:17:44 ON 31 JUL 2007
```

FILE COVERS 1907 - 31 Jul 2007 VOL 147 ISS 6
FILE LAST UPDATED: 30 Jul 2007 (20070730/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 4 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:619495 CAPLUS
DOCUMENT NUMBER: 147:72744
TITLE: Anti-angiogenesis compounds
INVENTOR(S): Park, Joong Wan
PATENT ASSIGNEE(S): HIF Bio, Inc., USA; Nishnotech Co., Ltd.
SOURCE: PCT Int. Appl., 183pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007065810	A1	20070607	WO 2006-US46267	20061204

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-741742P P 20051202

OTHER SOURCE(S): MARPAT 147:72744
GI



AB Process for preparation of 3-heterocyclyl-substituted pyrazole derivative [I; R1 = aromatic saturated (un)substituted ring; R2 = 6-membered heterocyclic ring, aromatic

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 940927-47-9 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-2-[5-[(2-fluorophenyl)methyl]-1H-indazol-3-yl]- (CA INDEX NAME)



RN 940927-48-0 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-2-[5-[(2-fluorophenyl)methyl]-1H-indazol-3-yl]-6-methyl- (CA INDEX NAME)

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
or satd. (un)substituted heterocyclic ring; R3 and R4 = including double bond form 5-membered arom. heterocyclic ring or a (un)substituted Ph ring], their isomers or salts as anti-angiogenesis compds. for inhibition of HIF and HIF regulated genes expression in tumor cells or tissue, inducing cell cycle arrest and treating cell proliferating diseases or conditions was developed. Thus, compd. (II) were synthesized in 50% yield

via redn. of prepd. by multistep synthesis

3-(5-(1,7,-dioxan-2-yl)furan-2-
yl)-1-(4-picolyl)indazole with NaBH. The compds. of the invention induce cell cycle arrest in HepJB liver tumor cells.

IT 940927-45-7P 940927-46-8P 940927-47-9P
940927-48-0P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn of heterocyclyl-substituted pyrazole derivative as anti-angiogenesis
compds. for inhibition of HIF expression in tumor cells or tissue inducing cell cycle arrest and treating cell proliferating diseases or conditions)

RN 940927-45-7 CAPLUS
CN 4-Pyrimidinamine, 5-fluoro-2-[1-[(2-fluorophenyl)methyl]-1H-indazol-3-yl]- (CA INDEX NAME)

RN 940927-46-8 CAPLUS
CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-indazol-3-yl]-5-methyl- (CA INDEX NAME)

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:389203 CAPLUS
DOCUMENT NUMBER: 140:353693
TITLE: Preparation of morpholine-bridged indazoles as cGMP stimulators
INVENTOR(S): Feurer, Achim; Lustig, Joachim; Wirtz, Stephan-Nicholas; Koenig, Gerhard; Stasch, Johannes-Peter; Wunder, Frank; Lang, Dieter; Stahl, Elke; Schenke, Thomas; Schreuder, Rudy
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 21 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10244912	A1	20040409	DE 2002-10244912	20020926
CA 2500008	A1	20040415	CA 2003-2500008	20030916
WO 2004031176	A1	20040415	WO 2003-EP10273	20030916
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003278885	A1	20040423	AU 2003-278885	20030916
EP 1546147	A1	20050629	EP 2003-757949	20030916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006528702	T	20061221	JP 2004-540624	20030916
US 2006128720	A1	20060615	US 2005-528601	20051014
PRIORITY APPLN. INFO.:			DE 2002-10244912	A 20020926
			WO 2003-EP10273	W 20030916

OTHER SOURCE(S): MARPAT 140:353693
GI



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 677004-47-6 CAPLUS
CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-indazol-3-yl]-5-[8-oxa-3-azabicyclo[3.2.1]oct-3-yl]- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)





AB Title compds. [I; R1 = Q1, Q2; n = 1, 2; R2 = H, NH2], were prepd for the production of drugs for treating diseases of the central nervous system. Thus, 1-(2-fluorobenzyl)-1H-indazole-3-carbonitrile (preparation given) and (R)-2-cyano-2-(3-oxa-9-azabicyclo[3.3.1]non-9-yl)ethylacetate (preparation given) in PhMe were stirred over night at 120° to give 4% 2-[1-(2-fluorobenzyl)-1H-indazol-3-yl]-5-(3-oxa-9-azabicyclo[3.3.1]non-9-yl)-4-pyrimidylamine. The latter at 0.1 μM showed statistically significant increase of cGMP in primary cortex-neurons.

IT 677004-46-5P 677004-47-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of morpholine-bridged indazoles as cGMP stimulators)

RN 677004-46-5 CAPLUS
CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-indazol-3-yl]-5-[3-oxa-9-azabicyclo[3.3.1]non-9-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:262075 CAPLUS
DOCUMENT NUMBER: 132:279231
TITLE: Preparation of 1-benzyl-3-(pyrimidin-2-yl)indazoles and related compounds as stimulators of soluble guanylate cyclase
INVENTOR(S): Feurer, Achim; Straub, Alexander; Furstner, Chantal; Stasch, Johannes-Peter; Perzborn, Elisabeth; Kutter, Joachim; Denbowsky, Klaus
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023454	A1	20000420	WO 1999-EP7202	19990929
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, SW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
DE 19946514	A1	20000420	DE 1998-19946514	19981009
CA 2346698	A1	20000420	CA 1999-2346698	19990929
AU 9963909	A1	20000501	AU 1999-63909	19990929
EP 1119556	A1	20010801	EP 1999-950564	19990929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
JP 2002527475	T	20020827	JP 2000-577560	19990929
PRIORITY APPLN. INFO.:			DE 1998-19846514	A 19981009
			WO 1999-EP7202	W 19990929

OTHER SOURCE(S): MARPAT 132:279231
GI

AB Title compds. [I; R1 = (substituted) 6-membered heteroaryl; R2R3 = atoms to form a (substituted) Ph ring; A = (substituted) Ph, aromatic or saturated 5-6

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
membered heteroaryl, were prepd. Thus, 1-(2-fluorobenzyl)indazole-3-amidinium chloride (prepn. given) was stirred 5 min. in MeOH contg. NaOMe; 2-(2-pyridyl)-3-dimethylaminoacrylonitrile was added and the mix. was refluxed overnight to give 40% 3-[4-amino-5-(2-pyridyl)-2-pyrimidinyl]-1-[(2-fluorophenyl)methyl]indazole. I showed blood vessel relaxing activity with IC50:0.10 uM.
IT 264123-71-9P 264123-72-0P 264123-73-1P
264123-74-2P 264123-75-3P 264123-76-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-benzyl-3-(pyrimidin-2-yl)imidazoles and related compds. as stimulators of soluble guanylate cyclase)
RN 264123-72-0 CAPLUS
CN 4-Pyrimidinamine, 2-[1-[(2-fluorophenyl)methyl]-1H-indazol-3-yl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 264123-73-1 CAPLUS
CN 4-Pyrimidinamine, 2-[3-[(2-fluorophenyl)methyl]-1H-indazol-3-yl]-5-(2-pyridinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 264123-74-2 CAPLUS
CN Phosphonic acid, [4-amino-2-[3-[(2-fluorophenyl)methyl]-1H-indazol-3-yl]-5-pyrimidinyl]-, diethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 264123-75-3 CAPLUS
CN Phosphonic acid, [4-amino-2-[3-[(2-fluorophenyl)methyl]-1H-indazol-3-yl]-5-pyrimidinyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)



RN 264123-76-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-amino-2-[3-[(2-fluorophenyl)methyl]-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:83169 CAPLUS
DOCUMENT NUMBER: 132:122629
TITLE: Preparation of pyrimidinylpyrazolopyridines and related compounds as cardiovascular agents.
INVENTOR(S): Stasch, Alexander; Feurer, Achim; Alonso-Alija, Cristina; Stahl, Elke; Staesch, Johannes-Peter; Perzborn, Elisabeth; Buetter, Joachim; Dembowsky, Klaus
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 76 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19834047	A1	20000203	DE 1998-19834047	19980729
WO 2000006568	A1	20000210	WO 1999-EP5073	19990716
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9952839	A1	20000221	AU 1999-52839	19990716
EP 1102767	A1	20010530	EP 1999-938272	19990716
EP 1102767	B1	20051102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002521482	T	20020716	JP 2000-562370	19990716
ES 2251213	T3	20060416	ES 1999-938272	19990716
US 6833364	B1	20041221	US 2001-744703	20010326
PRIORITY APPLN. INFO.:			DE 1998-19834047 A	19980729
			WO 1999-EP5073 W	19990716

OTHER SOURCE(S): MARPAT 132:122629
GI

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. [I; R1 of R1, X, Y = (substituted) (unsatd.) cycloalkyl, the rest = H, amino, NO, CHO, SH, OH, COOH, aryl, alkoxy, etc.; R2R3 = atoms to form (substituted) Ph, 6-membered saturated or aromatic heteroaryl; A = (substituted) 5-6 membered aromatic or saturated heterocyclic ring); were prepared Thus, 3-[4-amino-5-cyclopropylpyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine (preparation from 2-cyclopropyl-2-dimethylaminoacrylonitrile and the corresponding uridine given) inhibited thrombocyte aggregation with IC50 = 3 nM.
IT 256376-88-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidinylpyrazolopyridines and related compds. as cardiovascular agents)
RN 256376-88-2 CAPLUS
CN 4-Pyrimidinamine, 5-cyclopropyl-2-[1-[(2-fluorophenyl)methyl]-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                    21.55      193.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                    -3.12       -3.12

STN INTERNATIONAL LOGOFF AT 13:18:01 ON 31 JUL 2007
```